Burning Rock Biotech will hold its annual general meeting on December 22, 2026, seeking ratification of Ernst & Young Hua Ming LLP as auditor and re-election of directors Zhihong (Joe) Zhang and Wendy Hayes.
BNR · Burning Rock Biotech Ltd
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $13.32
- Open
- $13.29
- Day range
- $12.98–14.31
- 52-week closing range
- $7.04–41.06
- Average volume, 30 days
- 24K
- Short interest
- 34K · 0.3% of shares · 1.3 days
- Short volume, last session
- 58%
- Last earnings
- Mar 29, 2024
- Price history
- Jun 2020 to Nov 2026
Up next
Latest documents
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNR
this stock
Burning Rock Biotech Ltd
|
$140.48M | -33.9% | +9.2% | — | 0.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$255.19B | +18.9% | +14.5% | 36.3 | 1.3% |
|
DHR
Danaher Corp
|
$160.10B | -0.6% | +8.5% | 37.2 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$54.33B | +1.9% | +10.4% | 46.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.43B | +28.9% | +6.4% | 34.5 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 5
Burning Rock Biotech will hold its annual general meeting on December 22, 2026, seeking ratification of Ernst & Young Hua Ming LLP as auditor and re-election of directors Zhihong (Joe) Zhang and Wendy Hayes.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNR | -0.1% | +0.5% | +42.9% | +22.2% | -33.9% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +5.4% | +6.8% | +48.6% | +27.5% | -38.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.